바이오인

1. OECD 생명공학작업반의 개요
가. OECD 생명공학작업반(WPB)의 역할 ································1
나. OECD 생명공학작업반의 추진체계 ···································2
다. OECD 생명공학작업반의 역사 ···········································4
라. OECD 생명공학작업반 주요 국가들 ·································7

2. OECD 생명공학작업반 주요의제
가. OECD 생명공학작업반 주요 의제 분류 ···························9

나. 바이오기술 정책 ···································································10
1) 바이오기술에 대한 경제적 평가 ························································10
2) 바이오기술혁신과 의료비 ····································································12
3) 고령화(Aging) ··························································································14
4) OECD 보건혁신 전략 ···········································································16
5) 지식재산권을 위한 협동메카니즘 ······················································21
6) 유전자발명의 면허를 위한 가이드라인 ············································22
7) 위조 및 저작권 침해의 경제적 영향 ················································22
8) 지식시장 ··································································································25
9) OECD 바이오경제 프로젝트 ·······························································28
10) 혁신 그리고 바이오 안보성(biosecurity) ··········································30

다. OECD 생명공학통계 분석 ·················································33
1) 개요 ··········································································································33
2) BT투자 및 기업 ······················································································35
3) BT에 대한 성과 ······················································································38
4) 정책적 시사점 ························································································40

라. 보건의료 바이오 기술 ·························································51
1) 바이오 마커 ····························································································51
2) 생물자원센터 ··························································································53
3) 글로벌 생물자원센터 네트워크 ··························································54
4) 합성생물학 ······························································································56
5) 분자유전자테스트에 대한 품질인증 ··················································61
6) “새롭게 발견되거나 그동안 무관심하였던 감염증의 대처를 위한 의약”에 대한 OECD 고위급 포럼
····································································67

마. 산업적 바이오 기술 ·····························································71
1) 산업적 생명공학기술 ············································································71
2) 친환경, 청정산업을 위한 생명공학기술(Bioremediation) ················73
3) 바이오기술 생산품의 실질적 동등성 논의 ······································75
4) 음용수 ······································································································76

3. OECD 생명공학작업반 국내 활동 동향
가. OECD 생명공학작업반 과제 현황 ···································78
나. OECD 생명공학작업반 관련회의 참가 현황 ·················80
다. OECD 생명공학작업반 과제 추진의 문제점 ·················82
라. OECD 생명공학작업반 과제의 개선방안 ·······················83

부록 1
OECD 생명공학작업반 회의 결과 모음(’06∼’08) ················87
OECD 생명공학작업반 과제 교과부 보고(’07∼’08) ·········· 125

부록 2
OECD 생물자원센터를 위한 OECD모범운영지침